KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Leases (2019 - 2025)

CRISPR Therapeutics AG's Current Leases history spans 7 years, with the latest figure at $18.6 million for Q4 2025.

  • For Q4 2025, Current Leases rose 7.46% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $18.6 million, up 7.46%, while the annual FY2025 figure was $18.6 million, 7.46% up from the prior year.
  • Current Leases for Q4 2025 was $18.6 million at CRISPR Therapeutics AG, up from $18.3 million in the prior quarter.
  • Across five years, Current Leases topped out at $18.6 million in Q4 2025 and bottomed at $8.3 million in Q2 2022.
  • The 5-year median for Current Leases is $15.8 million (2022), against an average of $15.0 million.
  • The largest annual shift saw Current Leases plummeted 47.92% in 2022 before it skyrocketed 79.42% in 2023.
  • A 5-year view of Current Leases shows it stood at $12.2 million in 2021, then soared by 30.3% to $15.8 million in 2022, then fell by 1.37% to $15.6 million in 2023, then grew by 10.64% to $17.3 million in 2024, then increased by 7.46% to $18.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Current Leases are $18.6 million (Q4 2025), $18.3 million (Q3 2025), and $18.0 million (Q2 2025).